GPBAR1 and metabolic dysfunction-associated steatotic liver disease: The suppression of FXR and Takeda G protein-coupled receptor 5 (TGR5)-signalling in MASLD leads to detrimental alterations in hepatic glucose and lipid homeostasis and the exacerbation of hepatic steatosis and systemic metabolic dysfunction (Figure 3) [34].